- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
The Scientific World Journal
Volume 2012 (2012), Article ID 979867, 5 pages
Prevalence of Clinically Significant Extraosseous Findings on Unenhanced CT Portions of 18F-Fluoride PET/CT Bone Scans
Department of Nuclear Medicine, Yuan's General Hospital, 162 Cheng-Kung 1st Road, Kaohsiung 802, Taiwan
Received 13 June 2012; Accepted 24 August 2012
Academic Editors: A. Frenkel, P. Hartvig, and D. Morris
Copyright © 2012 Chao-Jung Chen and Shih-Ya Ma. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. Due to the frequently interrupted supply of 99mTc-methylene diphosphonate, the use of 18F-fluoride positron emission tomography (PET)/computed tomography (CT) has become more popular. The study aims to determine the percentage of extraosseous findings from the unenhanced CT portion of 18F-fluoride PET/CT scans. Materials and Methods. We retrospectively collected 18F-fluoride PET/CT studies between March 2010 and February 2011. The unenhanced CT portions of 18F-fluoride PET/CT were reviewed for each patient. Significant extraosseous findings related to malignancy from the unenhanced CT were recorded. Results. A total of 158 patients (110 females, 48 males) were included in the study. Clinically significant extraosseous findings from the unenhanced CT were found in 43 patients (27.2%). Previously unknown extraosseous findings were identified in 17 patients (10.8%) after a review of the 18F-fluoride PET/CT scan results. Most of the extraosseous findings were small pulmonary metastases or enlarged metastatic lymph nodes. Conclusion. It is not rare to identify new clinically significant extraosseous findings from the unenhanced CT of 18F-fluoride PET/CT studies. Therefore the clinical management of patients may be altered by the results, and a careful review of the unenhanced CT portion of 18F-fluoride PET/CT is mandatory.
18F-fluoride is a tracer element for bone scintigraphy that was introduced by Blau and others in the early 1960s. It was approved for clinical use by the U.S. Food and Drug Administration in 1972. However, the relatively high energy of the 511-keV annihilation photons produced by the decay of 18F prohibited its widespread use in the era of Anger-type γ-cameras suitable for the 140-keV photons of 99mTc. 99mTc-methylene diphosphonate (MDP) was therefore the most suitable technique for whole-body surveys due to its wide availability and consistent low cost .
The successful development of positron emission tomography (PET)/computed tomography (CT) and the frequent interruption of 99mTc-MDP supply have led to a renewed interest in the use of 18F-fluoride PET/CT to detect bone metastases in cancer patients. Although the CT portion of the scan is mainly used for anatomic localization and attenuation correction, the scan might contain valuable information not shown on the PET image. Clinically significant findings from the unenhanced CT portion of 18F-fluorodeoxyglucose (FDG) PET/CT and myocardial perfusion single photon emission computed tomography (SPECT)/CT have been discussed [2–4]. To our knowledge, no information currently exists on the utility of the unenhanced CT portion from 18F-fluoride PET/CT. The purpose of this study was to assess the prevalence of clinically significant extraosseous findings from the unenhanced CT portions of 18F-fluoride PET/CT.
2. Materials and Methods
The study retrospectively included patients with known or suspected malignancy that underwent 18F-fluoride PET/CT studies for the detection of bone metastasis either for staging or followup between March 2010 and February 2011. The study protocol was approved by the institutional review board.
2.1. 18F-Fluoride PET/CT
Each patient was given 370 MBq (10 mCi) of 18F-fluoride intravenously. Subsequently, an integrated PET/CT scanner (Biograph; Siemens AG, Berlin, Germany) was used to acquire full body images 1 h after injection. The emission data acquisition time per bed was 3 minutes. The 6-slice CT was acquired using the following scanning parameters: 130 kVp, 95 mA, PITCH: 1.5, slice thickness: 3 mm. No CT contrast agent was administered. Both PET and CT scans were performed for patients under shallow breathing. All patients placed their arms at their sides during the CT acquisition. The images were reconstructed with a standard ordered-subset expectation maximization algorithm.
2.2. CT Interpretation
Two experienced board-certified nuclear medicine physicians reviewed the unenhanced CT scans using soft tissue, lung, and bone window settings. All skeletal findings from the unenhanced CT were excluded. Extraosseous findings from the unenhanced CT were considered significant and recorded if they were suspected to be malignant. Other extraosseous findings not related with malignancy, such as renal stone, were judged as nonsignificant and excluded. The clinically significant extraosseous findings from the unenhanced CT of 18F-fluoride PET/CT were compared with the previous exams and separated into either previously known or unknown groups. All patients had comparisons with followup imaging studies to confirm the findings from the unenhanced CT of 18F-fluoride PET/CT and to check for the existence of any missed lesions.
A total of 158 patients were recruited in the study. There were 110 female patients and 48 male patients. The average age was 57 years old (range: 31–84 years old). These patients had diverse malignancies including 92 breast cancers, 16 hepatocellular carcinomas (HCC), 9 lung cancers, 7 nasopharyngeal carcinomas, 4 buccal cancers, 4 colon cancers, 4 esophageal cancers, 4 prostate cancers, 4 tongue cancers, and 14 other forms of cancer.
43 patients (27.2%) demonstrated clinically significant extraosseous findings from the unenhanced CT of 18F-fluoride PET/CT. After excluding previously known cases, 17 patients (10.8%) showed clinically significant new extraosseous findings (Table 1). Small pulmonary metastases were identified in 10 patients (Figure 1). Enlarged metastatic lymph nodes were found in 6 patients (Figure 2). Incidental primary malignancies, including lung and breast cancer (Figure 3), were discovered in two patients.
Unenhanced CT from 18F-fluoride PET/CT was unable to identify HCC tumors in 9 of 16 patients with either primary or recurrent hepatic tumors detected with concurrent CT or magnetic resonance imaging (MRI). Further retrospective review of the CT results only identified obscure images.
18F-fluoride PET has been proven to be more useful than 99mTc-MDP scintigraphy for detection of bone metastasis in a variety of malignancies [5, 6]. With the aid of CT, 18F-fluoride PET/CT is better than 18F-fluoride PET alone and is more accurate than 99mTc-MDP scintigraphy when compared to SPECT/CT [7–9]. Although the original role of CT in 18F-fluoride PET/CT is for identifying anatomic landmarks, it also provides a large amount of diagnostic information. Our study showed that most extraosseous findings occurred in the lungs. Given that low dose CT without contrast enhancement has been used widely in lung cancer screening for many years [10, 11], it is not surprising that the unenhanced CT in the PET/CT can also detect pulmonary lesions. These previously unknown small pulmonary metastases detected by the unenhanced CT of PET/CT could influence the future clinical management of these patients. Chest X-rays which are routinely used for followup care in lung cancer patients are not efficient at detecting small pulmonary nodules. In patients with HCC, the followup abdominal CT only images the lower part of the lung. Furthermore, the use of an additional low-dose CT scan during maximal inspiration after a PET/CT scan has been suggested . However, based on our experience, the unenhanced CT portion of 18F-fluoride PET/CT with shallow breathing can detect the same pulmonary lesions as conventional contrast enhanced chest CT. The second most common extraosseous findings identified in this study were enlarged metastatic lymph nodes. Based on these results, contrast enhancement is not necessary for detection of metastatic lymph nodes . Careful CT image analysis makes identifying metastatic lymph nodes possible. Primary malignancies, including lung and breast cancer, were incidentally observed in two patients. These findings suggest the possibility of using unenhanced CT of 18F-fluoride PET/CT for early detection for primary malignancy. The above-mentioned clinically significant extraosseous findings from the unenhanced CT of 18F-fluoride PET/CT show that this test can be used to identify previously unknown malignancies, and these results urge further study. Identifying additional lesions using this technique may lead to changes in the therapeutic management of patients.
Although unenhanced CT may provide diagnostic information, there are limitations to this test. Without contrast enhancement, the CT poorly detects lesions in the solid organs such as the liver . In our study, no hepatic tumors were found using unenhanced CT of PET/CT. Solid organ lesions missed by CT could be addressed by using abdominal ultrasonography as a complementary tool. The addition of contrast enhancement in 18F-FDG PET/CT has been widely discussed and can contribute additional information . Conversely, no studies on contrast enhancement have been conducted with the 18F-fluoride PET/CT because CT is primarily used for lesion localization. Future use of contrast enhancement may permit the identification of previously undetectable liver lesions, thus reducing the necessity of abdominal ultrasonography.
The present study using unenhanced CT to image extraosseous lesions has limitations. First, it was a retrospective study and the 18F-fluoride PET/CT was only performed when 99mTc-MDP was unavailable. Therefore, a potential bias in patient selection is possible. Second, with the exception of breast cancer patients, the total number of patients with other forms of cancer is small. The actual percentage and importance of clinically significant extraosseous findings from unenhanced CT in other kinds of malignancy are uncertain. A large prospective study for a specific malignancy comparing CT with conventional radiological studies is needed. Finally, this study could be criticized because the unenhanced CT portion of PET/CT was not reviewed by radiologists or nuclear medicine physicians with additional CT training [2, 3, 16, 17]. However, in our study no potentially visible lesions were missed in the unenhanced CT portion of 18F-fluoride PET/CT when compared with followup studies such as contrast enhanced CT, MRI, or 18F-FDG PET/CT. Moreover, most nuclear medicine physicians also review the unenhanced CT in their daily practice of analyzing 18F-FDG PET/CT. Nuclear medicine physicians are capable of interpreting the unenhanced CT portion of 18F-fluoride PET/CT .
The frequent shortages and uncertain future supply of 99Mo may be a potential crisis that reduces the consistent use of 99mTc-MDP bone scintigraphy. In contrast, the supply of 18F-fluoride is increasing because of its wide spread use in cyclotrons. Although 18F-fluoride is currently more expensive than 99mTc-MDP, the price differential could decrease due to the increasing availability of cyclotrons. In addition, regular followup for cancer patients commonly includes basic tests such as chest X-ray and abdominal ultrasonography. 18F-fluoride PET/CT with contrast enhancement can provide information for the entire skeletal system. This information cannot easily be obtained with other radiological images and can reduce the cost associated with chest X-rays and abdominal ultrasonography. The CT of 18F-fluoride PET/CT can detect pulmonary nodules less than 1 cm in diameter, which are difficult to verify by chest X-ray, and has the ability to detect enlarged lymph nodes through a whole body survey. By using contrast enhancement, potential lesions in solid organs such as the liver may also be detected. Contrast enhanced CT may lead to the replacement of abdominal ultrasonography. In the future, contrast enhanced 18F-fluoride PET/CT may be used in the followup of cancer patients. However, further studies are needed to determine whether this approach is cost-effective.
According to our preliminary data, it is not uncommon to locate previously undetected, clinically significant, extraosseous findings using unenhanced CT in the 18F-fluoride PET/CT. These new findings may have a great impact on the therapeutic planning and treatment of patients. Routinely and carefully reviewing the unenhanced CT portion of 18F-fluoride PET/CT is necessary.
- F. D. Grant, F. H. Fahey, A. B. Packard, R. T. Davis, A. Alavi, and S. T. Treves, “Skeletal PET with 18F-fluoride: applying new technology to an old tracer,” Journal of Nuclear Medicine, vol. 49, no. 1, pp. 68–78, 2008.
- M. M. Osman, C. Cohade, E. K. Fishman, and R. L. Wahl, “Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: frequency in 250 patients,” Journal of Nuclear Medicine, vol. 46, no. 8, pp. 1352–1355, 2005.
- L. Husmann, F. Tatsugami, U. Aepli et al., “Prevalence of noncardiac findings on low dose 64-slice computed tomography used for attenuation correction in myocardial perfusion imaging with SPECT,” International Journal of Cardiovascular Imaging, vol. 25, no. 8, pp. 859–865, 2009.
- S. Goetze, H. K. Pannu, and R. L. Wahl, “Clinically significant abnormal findings on the “nondiagnostic” CT portion of low-amperage-CT attenuation-corrected myocardial perfusion SPECT/CT studies,” Journal of Nuclear Medicine, vol. 47, no. 8, pp. 1312–1318, 2006.
- H. Schirrmeister, A. Guhlmann, K. Elsner et al., “Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET,” Journal of Nuclear Medicine, vol. 40, no. 10, pp. 1623–1629, 1999.
- H. Schirrmeister, G. Glatting, J. Hetzel et al., “Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer,” Journal of Nuclear Medicine, vol. 42, no. 12, pp. 1800–1804, 2001.
- E. Even-Sapir, U. Metser, G. Flusser et al., “Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT,” Journal of Nuclear Medicine, vol. 45, no. 2, pp. 272–278, 2004.
- E. Even-Sapir, U. Metser, E. Mishani, G. Lievshitz, H. Lerman, and I. Leibovitch, “The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT,” Journal of Nuclear Medicine, vol. 47, no. 2, pp. 287–297, 2006.
- R. F. Yen, C. Y. Chen, M. F. Cheng et al., “The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients,” Nuclear Medicine Communications, vol. 31, no. 7, pp. 637–645, 2010.
- G. Veronesi, M. Bellomi, J. L. Mulshine et al., “Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules,” Lung Cancer, vol. 61, no. 3, pp. 340–349, 2008.
- H. MacMahon, J. H. M. Austin, G. Gamsu et al., “Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society,” Radiology, vol. 237, no. 2, pp. 395–400, 2005.
- H. Kuehl, P. Veit, S. J. Rosenbaum, A. Bockisch, and G. Antoch, “Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen,” Journal of Nuclear Medicine, vol. 48, no. 1, pp. 45S–57S, 2007.
- B. Rodríguez-Vigil, N. Gómez-León, I. Pinilla et al., “PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT,” Journal of Nuclear Medicine, vol. 47, no. 10, pp. 1643–1648, 2006.
- M. J. Gollub, R. Hong, D. M. Sarasohn, and T. Akhurst, “Limitations of CT during PET/CT,” Journal of Nuclear Medicine, vol. 48, no. 10, pp. 1583–1591, 2007.
- G. Antoch, L. S. Freudenberg, T. Beyer, A. Bockisch, and J. F. Debatin, “To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT,” Journal of Nuclear Medicine, vol. 45, pp. 56S–65S, 2004.
- H. Schöder, H. W. D. Yeung, and S. M. Larson, “CT in PET/CT: essential features of interpretation,” Journal of Nuclear Medicine, vol. 46, no. 8, pp. 1249–1251, 2005.
- R. E. Coleman, D. Delbeke, M. J. Guiberteau et al., “Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance,” Journal of Nuclear Medicine, vol. 46, no. 7, pp. 1225–1239, 2005.